Key facts
- This page summarizes Peter Greenleaf's Form 4 filing for Aurinia Pharmaceuticals Inc. (AUPH).
- 5 reported transactions and 1 derivative row are listed below.
- Accepted by SEC: 04 Mar 2025, 21:02.
Peter Greenleaf - 28 Feb 2025 Form 4 Insider Report for Aurinia Pharmaceuticals Inc. (AUPH)
- Reporting relationship
- Chief Executive Officer, Director
- Issuer ticker
- AUPH
- Reported as of
- 28 Feb 2025
- Net transaction value
- -$2,871,124
- SEC form
- 4
- Accepted by SEC
- 04 Mar 2025, 21:02:08 UTC
- Prior SEC filing
- 07 Mar 2024
- Next SEC filing
- 07 Jul 2025
- Source filing
- View source filing
- Reporting owner signature
- /s/ Peter S. Greenleaf
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
Peter Greenleaf filed Form 4 for Aurinia Pharmaceuticals Inc. (AUPH) on 04 Mar 2025.
Change
- Previous filing in this sequence was filed on 07 Mar 2024.
- Current net transaction value: -$2,871,124.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
AUPH
transaction
Common Stock
Award
- Transaction value
- $0
- Shares
- +290,728
- Change %
- +19%
- Price
- $0.000000
- Shares after
- 1,815,780
- Date
- 28 Feb 2025
- Ownership
- Direct
- Footnotes
- F1, F2
AUPH
transaction
Common Stock
Award
- Transaction value
- $0
- Shares
- +333,705
- Change %
- +18%
- Price
- $0.000000
- Shares after
- 2,149,485
- Date
- 03 Mar 2025
- Ownership
- Direct
- Footnotes
- F3
AUPH
transaction
Common Stock
Sale
- Transaction value
- $1,564,744
- Shares
- -195,593
- Change %
- -9.1%
- Price
- $8.00
- Shares after
- 1,953,892
- Date
- 03 Mar 2025
- Ownership
- Direct
- Footnotes
- F4, F5
AUPH
transaction
Common Stock
Sale
- Transaction value
- $1,306,380
- Shares
- -164,947
- Change %
- -8.4%
- Price
- $7.92
- Shares after
- 1,788,945
- Date
- 04 Mar 2025
- Ownership
- Direct
- Footnotes
- F6, F7
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
AUPH
transaction
Derivative
Employee Stock Option (right to buy)
Award
- Transaction value
- $0
- Shares
- +443,973
- Change %
- Price
- $0.000000
- Shares after
- 443,973
- Date
- 28 Feb 2025
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 443,973
- Exercise price
- $7.55
- Footnotes
- F8
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 8 footnotes
Footnote F1
Each performance right represents a contingent right to receive one common share of the Issuer. The performance rights vest in four tranches upon the Issuer's common shares achieving four progressively higher target prices, with respective one year retention periods per tranche achievement.
Footnote F2
Includes common shares acquired by the reporting person pursuant to the Issuer's 2021 Employee Share Purchase Plan as follows: 2,500 common shares were acquired on May 31, 2024 and 438 common shares were acquired on November 29, 2024.
Footnote F3
Represents grant of performance award payable solely in common shares of the Issuer that vest in two (2) equal annual installments on December 31, 2024 and December 31, 2025.
Footnote F4
Represents the number of shares automatically sold to cover tax withholding obligations in connection with the vesting of Restricted Stock Units (RSUs) related to the February 20, 2024 grant and March 2, 2023 performance award.
Footnote F5
The price in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $7.79 to $8.13, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
Footnote F6
Represents the number of shares automatically sold to cover tax withholding obligations in connection with the vesting of RSUs related to the March 2, 2022 and March 2, 2023 grants.
Footnote F7
The price in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $7.76 to $8.10, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
Footnote F8
One-third of the shares subject to the option vests twelve months from the grant date, and the remainder vests in twenty-four equal monthly installments thereafter.